Comparative semiology of drug-induced uveitis related to Checkpoint inhibitors and MAP-kinase pathway inhibitors

被引：0
|
作者：
Thibault, T. [1 ]
Dautriche, A. [2 ]
Auvens, C. [1 ]
Brunel, P. [3 ]
Boulay, C. [4 ]
Atzenhoffer, M. [5 ]
Devilliers, H. [1 ]
Grandvuillemin, A. [2 ]
机构：
[1] Univ Hosp Dijon Bourgogne, Internal Med & Syst Dis Unit, Dijon, France
[2] Univ Hosp Dijon Bourgogne, Reg Pharmacovigilance Ctr Burgundy, Dijon, France
[3] Univ Hosp St Etienne, Reg Pharmacovigilance Ctr, St Etienne, France
[4] Univ Hosp Rouen, Dept Pharmacol, Reg Pharmacovigilance Ctr, Rouen, France
[5] Hospices Civils Lyon, Dept Pharmacol & Toxicol, Reg Pharmacovigilance Ctr, Lyon, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2023年 / 37卷
关键词：
checkpoint inhibitors; drug-induced uveitis; MAP-kinase pathway inhibitors;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
CO-056
引用
收藏
页码：41 / 41
页数：1
相关论文
共 50 条
  • [1] Drug-Induced Uveitis Related to Checkpoint Inhibitors and MAP-kinase Inhibitors
    Thibault, Thomas
    BEN Ghezala, Ines
    Freppel, Romane
    Rajillah, Abdessamad
    Boulay, Charlene
    Brunel, Pierre
    Atzenhoffer, Marina
    Auvens, Clement
    Devilliers, Herve
    Grandvuillemin, Aurelie
    OPHTHALMOLOGY, 2024, 131 (02) : 249 - 251
  • [2] Re: Thibault et al.: Drug-induced uveitis related to checkpoint inhibitors and MAP-kinase inhibitors ( Ophthalmology . 2024;131:249-251)-251)
    Francis, Jasmine H.
    Canestraro, Julia
    Abramson, David H.
    OPHTHALMOLOGY, 2024, 131 (07) : e31 - e32
  • [3] Re: Thibault et al.: Drug-induced uveitis related to checkpoint inhibitors and MAP-kinase inhibitors (Ophthalmology. 2024;131:249-251) Reply
    Thibault, Thomas
    Freppel, Romane
    Devilliers, Herve
    Grandvuillemin, Aurelie
    OPHTHALMOLOGY, 2024, 131 (07) : e32 - e32
  • [4] Natural and synthesized inhibitors of the MAP-kinase pathway study of their efficiency in vitro
    Saab, F.
    Routier, S.
    Beneteau, V.
    Merour, J. -Y.
    Schoentgen, F.
    EJC SUPPLEMENTS, 2008, 6 (09): : 147 - 147
  • [5] Functional and structural characterization of a novel class of MAP-kinase inhibitors
    Bartolini, Desiree
    Buhrmann, M.
    Barreca, Maria Letizia
    Manfroni, Giuseppe
    Cecchetti, Violetta
    Rauh, Daniel
    Galli, Francesco
    FREE RADICAL BIOLOGY AND MEDICINE, 2017, 108 : S65 - S65
  • [6] Drug-induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome
    Placais, Marion
    Laparra, Ariane
    Maria, Alexandre Thibault Jacques
    Kramkimel, Nora
    Perret, Audrey
    Manson, Guillaume
    Comont, Thibault
    Coutte, Laetitia
    Nardin, Charlee
    Ouali, Kaissa
    Danlos, Francois-Xavier
    Noel, Nicolas
    Messayke, Sabine
    Michel, Marc
    Lambotte, Olivier
    Michot, Jean-Marie
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1427 - 1430
  • [7] Activating TGF-beta Signalling Enhances the Efficacy of MAP-kinase Pathway Inhibitors in Melanoma
    Wellbrock, C.
    Smith, M.
    Ferguson, J.
    Arozarena, I.
    Hayward, R.
    Marais, R.
    Chapmann, A.
    Hurlstone, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S155 - S155
  • [8] Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors
    Franzese, Ornella
    Torino, Francesco
    Fuggetta, Maria Pia
    Aquino, Angelo
    Roselli, Mario
    Bonmassar, Enzo
    Giuliani, Anna
    D'Atri, Stefania
    ONCOTARGET, 2017, 8 (25) : 41641 - 41669
  • [9] Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database
    Anquetil, Celine
    Salem, Joe-Elie
    Lebrun-Vignes, Benedicte
    Touhami, Sara
    Desbois, Anne-Claire
    Maalouf, Georgina
    Domont, Fanny
    Allenbach, Yves
    Cacoub, Patrice
    Bodaghi, Bahram
    Saadoun, David
    JOURNAL OF AUTOIMMUNITY, 2020, 111
  • [10] Drug-Induced Liver Injury by Checkpoint Inhibitors: Benefit of a Causality Assessment Tool
    Weber, Sabine
    Benesic, Andreas
    Ishigami, Masatoshi
    Gerbes, Alexander L.
    HEPATOLOGY COMMUNICATIONS, 2020, 4 (10) : 1552 - 1554
12345